Here are five key notes:
1. The business combination will support Amendia’s focus on the spine market, with a comprehensive product offering in a vertically-integrated business model. The products are designed to maximize efficiencies, create cost-savings, customer service and creativity.
2. Custom Spine, a New Jersey-based company, has the rights to 40 patents, increasing Amendia’s breadth and depth of the research and development pipeline. The Custom Spine portfolio includes Pathway AVID, a signature technology.
3. The transaction positions Amendia for sustainable and scalable growth.
4. The Pathway AVID is an articulating vertebral interbody device providing optimal structural support while enhancing fusion. It includes three intra-linked PEEK cages inserted with the standard transforaminal approach.
5. Amendia was founded in 2008 and has technologies including the oblique lateral interbody fusion technique.
More articles on orthopedic devices:
8 things to know about Implanet in 2015 so far: Spine sales up 66%
5 notes about Medtronic CEO Omar Ishrak’s 79.8% increase in compensation
SeaSpine adds leaders: 6 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
